{"meta":{"query_hash":"28dc5cd371c0","filters":{"venue":"Journal des Anti-infectieux"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/28dc5cd371c0","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+des+Anti-infectieux"},"results":[{"id":"W2089392459","doi":"10.1016/j.antinf.2014.01.008","title":"Est-il possible qu’il n’y aura jamais de résistance contre le dolutégravir si ce médicament est utilisé en première ligne ?","year":2014,"lang":"fr","type":"article","venue":"Journal des Anti-infectieux","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dolutegravir; Human immunodeficiency virus (HIV); Drug resistance; Medicine; Virology; Antiretroviral therapy; Viral load; Genetics; Biology","score_opus":0.008311368478585312,"score_gpt":0.2520636880494709,"score_spread":0.24375231957088556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089392459","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0533491,0.03931408,0.0060378225,0.80647355,0.0068367403,0.00006482353,0.0003571849,0.00013242677,0.08743436],"genre_scores_gemma":[0.63541865,0.048762787,0.010141243,0.20254022,0.00911093,0.00014998551,0.00046550523,0.00017213874,0.09323852],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99659294,0.0015038591,0.00022225508,0.00040289128,0.00077783706,0.00050025],"domain_scores_gemma":[0.9892181,0.005484746,0.0014651264,0.00057098165,0.0024572057,0.00080396666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008163152,0.00036038624,0.00071897433,0.00038696156,0.0013782142,0.004418135,0.0010466824,0.0056022215,0.022316525],"category_scores_gemma":[0.02621458,0.00028507703,0.00084767473,0.00034648328,0.0032727022,0.0053581884,0.0009438706,0.0052737813,0.006268292],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003197099,0.00094976166,0.03439107,0.0020081254,0.00058217335,0.0050050286,0.00417375,0.0007225881,0.0059872367,0.14221467,0.13826986,0.66249865],"study_design_scores_gemma":[0.0003156237,0.00097293145,0.0121569885,0.003058701,0.00029619905,0.010602977,0.010990782,0.0010488331,0.004689816,0.14182904,0.8138833,0.00015479943],"about_ca_topic_score_codex":0.003584607,"about_ca_topic_score_gemma":0.0055263317,"teacher_disagreement_score":0.022316525,"about_ca_system_score_codex":0.0013899384,"about_ca_system_score_gemma":0.003532578,"threshold_uncertainty_score":0.07465619},"labels":[],"label_agreement":null}]}